Ò»¡¢Ñо¿±³¾°
ÂýÐÔÉöË¥½ß(Chronicrenal failure£¬CRF)ÊÇÖ¸·¢ÉúÔÚ¸÷ÖÖÂýÐÔÉöÔ༲²¡»ù´¡ÉÏ£¬ÓÉÓÚÉöµ¥Î»ºÍÉö¹¦ÄÜÊܵ½ÑÏÖØË𺦣¬µ¼ÖÂÉöСÇòÂ˹ýÂÊ(Glomerular filtration rate£¬GFR)Ͻµ£¬³öÏÖÌåÄÚ´úл²úÎïµÄäóÁô¡¢Ë®µç½âÖʺÍËá¼îƽºâʧµ÷¡¢ÄÚ·ÖÃÚÎÉÂÒµÄÒ»ÖÖ×ÛºÏÕ÷£¬ÊÇÉöÔ༰ÉöÔàÏà¹ØÐÔ¼²²¡µÄ×îÖÕ½á¾Ö[1]¡£
ÂýÐÔÉöË¥½ßÖ÷Òª²¡ÀíÌØµãΪ²»¶Ï½øÕ¹µÄÉöСÇòºÍÉö¼äÖʵÄÏËά»¯£¬ÊǼ¸ºõËùÓÐÀàÐ͵ÄÂýÐÔÉöÔಡ²»¶Ï·¢Õ¹Ö±ÖÁÖÕÄ©ÆÚÉö²¡(ESRD)µÄ¹²Í¬²¡Àí;¾¶[2-3]¡£5/6ÉöÔàÇгýÄ£ÐÍÊÇÒ»ÖÖ½ÏΪ³ÉÊìºÍ¾µäµÄÑо¿ÂýÐÔÉöË¥ÉöÔàÏËά»¯·¢Éú·¢Õ¹»úÖÆµÄʵÑéÄ£ÐÍ£¬ÉöÔàÇгýÖ®ºó£¬²Ð´æµÄÉöÔà³öÏÖ¸ßѹÁ¦¡¢¸ßÂ˹ý¡¢¸ß¹àע״̬£¬¼¤»îÑõ»¯Ó¦¼¤¡¢Ñ×Ö¢µÈ²¡Àí¹ý³Ì£¬¿É´Ù½øÉöÔàÏËά»¯µÄ·¢Éú£¬½ø¶øµ¼ÖÂÂýÐÔÉöË¥½ß¡£
¶þ¡¢ÊµÑé·½°¸
1¡¢ÊµÑ鶯ÎSD´óÊ󣬴ÆÐÛ¸÷°ë£¬6~8ÖÜÁ䣻
2¡¢CRFÄ£ÐÍÖÆ±¸[4]
´óÊóÊÊÓ¦ÐÔËÇÑø1ÖÜ£¬¸¹Ç»×¢Éä10%Ë®ºÏÂÈÈ©ÈÜÒºÂé×í£¬½«´óÊó¹Ì¶¨ÔÚÊÖÊõ°åÉÏ¡£Ê×ÏÈÔÚ´óÊóµÄ¼¹ÖùÁ½²àÉöÔಿλ½øÐÐÆ¤Ã«ÌÞ³ý£¬µâ·ü¶Ô´Ë²¿Î»³£¹æÏû¶¾£¬´©´÷ÎÞ¾úµÄÊÖÌ×£¬ÆÌ¸ÇÎÞ¾úµÄ¶´½í¡£È»ºóÑØÀß¼¹½ÇÐÐ×ó±³²¿Ð±ÇУ¬ÊÖÊõÇпÚԼΪ2.0~2.5cm£¬¼ô¿ª´óÊóµÄƤ·ô¼°¼¡È⣬ÓÃ×óÊÖ̽²é×óÉöËùÔÚ²¿Î»£¬²¢ÓÃÖÐÖ¸½«Æä´Ó¸¹²àÍùÇпڵķ½ÏòÍгö£¬Ê¹×ó²àÉöÔà³ä·Ö±©Â¶£¬ÓÃÄ÷×Ó¶ÔÉö°üĤ½øÐаþÀ룬²ÉÓÃ7ºÅÏß¶Ô×óÉöÉÏ¡¢Ï¼«½áÔú£¬½áÔú·¶Î§´óԼΪƤÖÊ2/3µÄÉö×éÖ¯£¬½«½áÔú²¿·ÖÇгýÍê±Ïºó£¬Á¢¼´ÓÃֹѪº£ÃàѹÆÈ×óÉöÉÏϼ«ÇпÚÒÔ½øÐÐֹѪ£¬µ±¹Û²ìµ½×óÉöÊÖÊõÇпÚÎÞÃ÷ÏԵijöѪºó¸´Î»×óÉöÔ࣬¶Ô¼¡È⡢Ƥ·ô½øÐÐÖð²ã·ìºÏºó£¬Óõâ·ü½øÐÐÊÖÊõ·ìºÏ¿ÚÏû¶¾¡£ÊõºóÁ¬Ðø3ÌìÓÃÇàÃ¹ËØ(8Íòµ¥Î»/100g¡¤d)¼¡Èâ×¢Éäɱ¾ú¿¹¸ÐȾ¡£1Öܺó½øÐеÚ2´ÎÊÖÊõ£¬ÔÚ¼¹ÖùÓÒ²àбÇпڣ¬°þÀ뼡²ã£¬³ä·Ö±©Â¶ÓÒÉöÔ࣬Ó÷ìºÏÏß½áÔúÓÒÉöÃŲ¿Î»ºó£¬Ö±½ÓÇгýÓÒ²àÉöÔ࣬Öð²ã·ìºÏºó½øÐÐÊÖÊõÇпÚÏû¶¾¡£Í¬Ñù¼¡×¢ÇàÃ¹ËØ(8Íòµ¥Î»/100g¡¤d)3Ìì¡£¼ÙÊÖÊõ×éÖÆ±¸µÄÊÖÊõ¹ý³Ìͬ5/6ÉöÇгýÊÖÊõ£¬µ«½ö×öË«Éö±»Ä¤°þÀëÊõ¡£
3¡¢¹Û²ìÖ¸±ê
3.1Éú»¯·¨¼ì²âѪÇ弡ôûScr¡¢ÄòËØµªBUN¡¢Äò¼¡ôûUcrµÄº¬Á¿£»
3.2 ÊÕ¼¯´óÊóµÄ24hÄòÒº£¬ELISA·¨¼ì²â24hÄòµ°°×µÄº¬Á¿£»
3.3 ¼ÆË㼡ôûÇå³ýÂÊCcr[5]
Ccr(ml/min/100g)=[Äò¼¡ôû(¦Ìmol/L)¡Á24СʱÄòÁ¿(ml)]£¯[Ѫ¼¡ôû(¦Ìmol/L)¡ÁÌåÖØ£¨g£©¡Á14.4]
3.4ÉöÔà×éÖ¯²¡Àíѧ¼ì²â¼°ÆÀ·Ö£ºHEȾɫ¡¢PASȾɫ¡¢MASSONȾɫ
¸ù¾Ý²Î¿¼ÎÄÏ×[6]¶ÔÉö¼äÖÊÏËά»¯³Ì¶È½øÐа붨Á¿ÆÀ·Ö£º
Ëæ»úѡȡ»¥²»Öصþ10¸öÊÓÒ°£¬400±¶ÏÔ΢¾µÏ¹۲죬°´ÏÂÁбê×¼¶ÔÉöÔಡÀí¸Ä±ä½øÐÐÆÀ·Ö£º
Éö¼äÖÊϸ°û½þÈóÆÀ·Ö£º
²¡Àí¸Ä±ä | ÆÀ·Ö |
ÎÞ¼äÖÊϸ°û½þÈó | 0·Ö |
¾ÖÔîϸ°û½þÈó | 1·Ö |
¶àÔîϸ°û½þÈó | 2·Ö |
ÃÖÂþϸ°û½þÈó | 3·Ö |
ÉöС¹ÜήËõºÍ¼äÖÊÏËά»¯µÄÂýÐÔ²¡±äÆÀ·Ö£º°´²¡±äÃæ»ýÕ¼¸ÃÊÓÒ°µÄ°Ù·Ö±È¼ÆËã
²¡Àí¸Ä±ä | ÆÀ·Ö |
ÎÞ¼äÖÊÏËά»¯ | 0·Ö |
¼äÖÊÏËά»¯£¼25% | 1·Ö |
25%¡Ü¼äÖÊÏËά»¯£¼50% | 2·Ö |
¼äÖÊÏËά»¯¡Ý50% | 3·Ö |
ÉöС¹ÜήËõ²¡±äÆÀ·Ö
²¡Àí¸Ä±ä | ÆÀ·Ö |
ÎÞÉöС¹ÜήËõ | 0·Ö |
ÉöС¹ÜήËõ£¼25% | 1·Ö |
25%¡ÜÉöС¹ÜήËõ£¼50% | 2·Ö |
ÉöС¹ÜήËõ¡Ý50% | 3·Ö |
Èý¡¢²Î¿¼ÎÄÏ×
[1] ¸ð¾ù²¨£¬ÐìÓÀ½¡£®ÄÚ¿ÆÑ§[M]£®8°æ£®±±¾©£ºÈËÃñÎÀÉú³ö°æÉ磬2013£º524£®
[2] Boor P£¬Ostendorf T£¬Floege J£®Renal fibrosis£ºnovel insights into mechanisms and therapeutic targets[J]£®Nat Rev Nephrol, 2010, 6(11)£º643-656£®
[3] Duffield JS£®Cellular and molecular mechanisms in kidney fibrosis[J]£®Journal of Clinical Investigation, 2014, 124(6)£º2299-2306£®
[5] Li HY, Hou FF£¬Zhang X£¬et a1£®Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model[J]. J Am Soc Nephrol, 2007£¬18(2)£º528-538£®
[6]³Â¬LÃÈ£¬ÓáСÃô£¬Ð¤½à. Äò¶¾Çå¿ÅÁ£ÒÖÖÆ´óÊóÉöÔà¼äÖÊÏËά»¯×÷ÓðеãÑо¿[J]. ºþÄÏÖÐÒ½Ò©´óѧѧ±¨£¬2017£¬37£¨1£©£º33-37.